Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain ...
June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
DEAR MAYO CLINIC: I have had an acoustic neuroma for 10 years. When it was first diagnosed, I had fractionated stereotactic radiosurgery. Since then, I've had 18 MRIs with gadolinium injections. Have ...
MERIDIAN, ID, UNITED STATES, February 11, 2026 /EINPresswire.com/ -- Raising Awareness, Educating Communities, and ...
PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...
In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results